Johnson & Johnson expects to have an efficacy readout on its coronavirus vaccine by January or February of 2021, Dr. Paul Stoffels, the company's chief scientific officer, said Thursday.
“The efficacy endpoint should be there in the first few weeks or months, January or February, in the new year,” Stoffels said at a conference sponsored by Reuters called the Reuters Total Health Conference.
Stoffels said the company is recruiting upwards of 1,000 people a day for its vaccine clinical trial and expects to reach its goal of 60,000 participants by the end of the year.
“It's not just the efficacy. It's also the safety,” Stoffels said. “We need half of the people having two months of exposure to the vaccine – as you probably know from the FDA guidelines – so that will bring us around the year end, early next year for having all the data.”
Stoffels said Johnson & Johnson is also working hard to meet diversity goals for its clinical trial.
Johnson & Johnson paused its trial in October due to an unexplained illness in a participant. Stoffels the independent Data Safety and Monitoring Board determined that illness was not related to the vaccine, and the company has not had any unexpected events since.
“The DSMB is looking very closely,” he added. “We have regular reviews on the safety, and so far, so good.”